Videos

A medical oncologist offers his initial impressions of the patient profile of a 60-year-old with early-stage NSCLC and discusses biomarker testing practices, highlighting types of testing and challenges.

Experts review best practices for identifying and diagnosing patients with lower-risk MDS.

Lori Wirth, MD, a medical oncologist, reviews the case of a 64-year-old woman with differentiated thyroid cancer (DTC).

Sandip P. Patel, MD, reviews the case of a 60-year-old woman with early-stage non–small cell lung cancer (NSCLC).

Patrick Forde, MBBCh, discusses the results of the TRIDENT-1 trial that led to the approval of repotrectinib for patients with metastatic ROS1 positive NSCLC.

Paula Rodriguez-Otero, MD, PhD, discusses the promising results from the phase 3 PERSEUS trial in patients with newly diagnosed, transplant-eligible multiple myeloma.

Adrian Cristian, MD, discusses the background of the third annual Miami Cancer Institute Oncology Rehabilitation Symposium and provides an overview of some of the topics that were presented this year.

Following their review of clinical trial data presented at SABCS 2023, the Oncology Brothers offer their key takeaways on recent updates in breast cancer.

Medical oncologists discuss recent data from KEYNOTE-522 looking at event-free survival with neoadjuvant and adjuvant pembrolizumab in triple-negative breast cancer.

Eleonora Teplinsky, MD, and the Oncology Brothers discuss recent updates from the ICARO study following the 2023 San Antonio Breast Cancer Symposium.

Experts on breast cancer review recent data updates from the IDEA trial investigating endocrine therapy without radiotherapy following breast-conserving surgery.

Following SABCS 2023, Eleonora Teplinsky, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from NSABP B-51 on loco-regional irradiation in patients who became node negative after neoadjuvant chemotherapy.

Guru P. Sonpavde, MD, provides insights on the phase 3 CheckMate 901 trial and explains what a community oncologist should know about the use of concurrent frontline nivolumab plus chemotherapy in metastatic or unresectable urothelial carcinoma based on this study.

Tanios Bekaii-Saab, MD, reviews real-world data and treatment sequencing for patients with metastatic colorectal cancer.

Matthew Lunning, DO, FACP, evaluates the clinical trial data from the L-MIND and RE-MIND2 studies, discussing the impact of tafasitamab + lenalidomide on real-world outcomes.

Dr. Lunning, an expert in lymphoma, discusses the results and clinical significance of the LOTIS-2 trial, evaluating loncastuximab tesirine for patients with R/R DLBCL.

Edward B. Garon, MD, MS, reviews the safety profiles of sacituzumab govitecan and datopotamab deruxtecan in patients with non–small cell lung cancer.

A brief overview of clinical trials investigating datopotamab deruxtecan in patients with non–small cell lung cancer.

Brooke Peters, PharmD, BCOP, offers a closing reflection on the transition from inpatient to outpatient treatment of bispecific antibodies.

A discussion on the evolving practices for administering bispecific T-cell engagers, from academic to community centers.

Dr. Peters shares clinical considerations for administering bispecifics, emphasizing the identification and mitigation strategies of late adverse events.

Expert regional community oncologist examines the grading and management of early adverse events such as CRS and ICANS, discussing the national guidelines that are utilized.

Expanding on the roles and responsibilities for executing a bispecifics administration program, highlighting a multidisciplinary collaboration to establish SOPs, training, and education.

BCG-unresponsive non-muscle invasive bladder cancer has multiple emerging treatment options in trials showing good response rates, though optimal sequencing remains to be determined.

Dr. Peters shares her experience in SOPs and program development for administration of bispecific T-cell engagers, noting program champions and key program components.

TAR-200 is being studied for carcinoma in situ with or without papillary disease since it addresses diffuse CIS that cannot be surgically removed, though future trials will expand to papillary disease as adjuvant therapy like BCG, with the goal of extending the disease-free period before potentially reintroducing therapy as needed.

Brooke Peters, PharmD, BCOP, provides a comprehensive overview of her institution’s bispecifics administration program, highlighting several agents and the hematologic/oncologic conditions they treat.

Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.

A clinical pharmacist explains how their practice has evolved related to the administration of bispecific T-cell engagers.

Justin LaPorte, PharmD, BCOP, presents information on the grading and management of early and late adverse events.